236 related articles for article (PubMed ID: 35239514)
1. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.
Bailey CM; Liu Y; Liu M; Du X; Devenport M; Zheng P; Liu Y; Wang Y
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35239514
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
[TBL] [Abstract][Full Text] [Related]
3. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
4. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
6. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
8. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.
Ding XC; Wang LL; Zhang XD; Xu JL; Li PF; Liang H; Zhang XB; Xie L; Zhou ZH; Yang J; Weichselbaum RR; Yu JM; Hu M
J Hematol Oncol; 2021 Jun; 14(1):92. PubMed ID: 34118979
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.
Tawadros AIF; Khalafalla MMM
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1063-S1069. PubMed ID: 30539847
[TBL] [Abstract][Full Text] [Related]
10. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
[TBL] [Abstract][Full Text] [Related]
11. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
[TBL] [Abstract][Full Text] [Related]
14. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer.
Sun J; Zhao Z; Lu J; An W; Zhang Y; Li W; Yang L
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612546
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway.
Zhao S; Gao J; Li J; Wang S; Yuan C; Liu Q
Inflammation; 2021 Oct; 44(5):1969-1981. PubMed ID: 34014492
[TBL] [Abstract][Full Text] [Related]
17. HIF-1α inhibits T-2 toxin-mediated "immune evasion" process by negatively regulating PD-1/PD-L1.
You L; Wang X; Wu W; Nepovimova E; Wu Q; Kuca K
Toxicology; 2022 Oct; 480():153324. PubMed ID: 36115646
[TBL] [Abstract][Full Text] [Related]
18. Deoxynivalenol upregulates hypoxia-inducible factor-1α to promote an "immune evasion" process by activating STAT3 signaling.
Zhang L; Wang X; Nepovimova E; Wu Q; Wu W; Kuca K
Food Chem Toxicol; 2023 Sep; 179():113975. PubMed ID: 37517547
[TBL] [Abstract][Full Text] [Related]
19. Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1α under Hypoxia.
Yong J; Gröger S; von Bremen J; Meyle J; Ruf S
Cells; 2022 Jul; 11(15):. PubMed ID: 35954195
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy.
Shurin MR; Umansky V
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35499071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
